

For a healthier
Tomorrow



In Epilepsy,
Recommend,
XBARENTM
Oxcarbazepine Sustained Release Tablets
150mg /300mg /450mg /600mg

La Renon[®]

XBARENTM

Oxcarbazepine Sustained Release Tablets

150mg /300mg /450mg /600mg

Indications

Xbaren is indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults and as monotherapy in the treatment of partial seizures in children aged 4 years and above with epilepsy, and as adjunctive therapy in children aged 2 years and above with partial seizures.

Mechanism of Action

Xbaren blocks voltage-sensitive sodium channels, which inhibits repetitive firing, stabilizes hyper-excited neuronal membranes and decreases release of synaptic impulses. These effects may prevent the spread of epileptic seizures.

Dosage

Adjunctive therapy for Adults- initiated with a dose of 600 mg/day, given in a twice-a-day regimen. If clinically indicated, the dose may be increased by a maximum of 600 mg/day at approximately weekly intervals.

- Conversion to Monotherapy for Adults – initiated at 600mg/day (given in a twice-a-day regimen) while simultaneously initiating the reduction of the dose of the concomitant AEDs. The concomitant AEDs should be completely withdrawn over 3-6 weeks.
- Initiation of Monotherapy for Adults - initiated at a dose of 600 mg/day (given in a twice-a-day regimen); the dose should be increased by 300 mg/day every third day to a dose of 1200 mg/day.
- Adjunctive therapy for Pediatric patients - In pediatric patients aged 4-16 years, treatment should be initiated at a daily dose of 8-10 mg/kg generally not to exceed 600 mg/day, given in a twice-a-day regimen.
- Conversion to Monotherapy for Pediatric patients – (Aged 4-16 years) - Initiated at approximately 8-10 mg/kg/day given in a twice-a-day regimen, while simultaneously initiating the reduction of the dose of the concomitant antiepileptic drugs. The concomitant antiepileptic drugs can be completely withdrawn over 3-6 weeks.
- Initiation of Monotherapy for Pediatric Patients - (Aged 4-16 years) - initiated at a dose of 8-10 mg/kg/day given in a twice-a-day regimen. The dose should be increased by 5 mg/kg/day every third day.
- Patients with Hepatic Impairment- Not required.
- Patients with Renal Impairment- In patients with impaired renal function (creatinine clearance <30 mL/min) Xbaren therapy should be initiated at one-half the usual starting dose (300 mg/day) and increased slowly to achieve the desired clinical response.

Presentation

Xbaren is available as film coated sustained release tablets in strengths of 150mg, 300mg, 450mg and 600mg.

La Renon[®]

La Renon Healthcare

208-Iscon Elegance, Circle P, Prahlad Nagar Cross Roads,
S.G.Highway, Ahmedabad-380015, Gujarat, India.
Phone: +91-79-3046-1000 (30 lines) Fax: +91-79-3046-1001
E-mail: info@larenon.com Web: www.larenon.com

I am _____
Call me on _____
Mail me at _____